20143rd International Conference

Santa Margherita Ligure - PortofinoMay 21–24, 2014

LEUKEMIA

Chairmen Angelo M. CarellaFelicetto FerraraEnrica Morra

SECTION OF HEMATOLOGY

2

20143rd International Conference

LEUKEMIA

PRESENTATIONThe Conference, with the participation of the most important International and Italian experts, wants to provide an update on the most innovative aspects of cellular and molecular biology, treatment of acute and chronic leukemias, myelodysplastic syndromes and Ph-negative chronic myeloproliferative syndrome. One section will be dedicated to the new drugs in onco-hematology.

ADDRESSED TOPhysicians specialized in Hematology, Oncology and Biologists.

OFFICIAL LANGUAGEThe meeting will be held in English. No simultaneous translation will be provided.

This Conference will be dedicated to Prof. John M. Goldman

3

PROGRAMME

WEDNESDAY, MAY 21

NEW DRUGS IN ONCO-HEMATOLOGY (not for CME credits)

Chairmen: Massimo FedericoPier Luigi Zinzani

14.00 Celgene pipeline and in early-development programs James Carmichael

14.15 Novelties in strategic approach to chronic hematological malignanciesAlf Bernhardt

14.30 An update of Brentuximab Vedotin and its future prospectiveAndreas Engert

14.45 New perspectives in acute leukemiasGiovanni Martinelli

15.00 Arsenic trioxide: many stories about an old product Giuseppe Rossi

15.15 New prospective in hematologyDaniele Alberti

15.30 The use of an adaptive trial design in a phase III trial of Vosaroxin and Cytarabine in relapsed and refractory AMLAdam Craig

16.00 New drugs anti-leukemiaDanilo Perrotti

CHALLENGES IN PHILADELPHIA-POSITIVE LEUKEMIAS

Chairmen: Robin Foà Angelo M. Carella

16.30 IntroductionRobin Foà

16.35 Current clinical options in Ph+ ALL Robin Foà

16.50 Early and deep molecular response predictive of long term outcome in Ph+ leukemias Giovanni Martinelli

17.05 Ponatinib: bridge to transplant and post transplant clinical strategiesFabio Ciceri

17.20 Conclusions and general discussionAngelo M. Carella

17.30 Round TableBONE MARROW TRANSPLANTATION IN LEUKEMIAS: NEW PERSPECTIVES

Chairmen: Alberto BosiAndrea Bacigalupo

Immunologic pressure after transplant and HLAFabio Ciceri

4

Unrelated donor transplant for leukemiaJane F. Apperley

Finding a donor for most eligible patientsWilliam Arcese

HDCT in MDS: indications, timing and optimization of the results. What’s new?Emanuele Angelucci

19.00 End of session

THURSDAY, MAY 22

8.00 Opening Ceremony

ACUTE MYELOID LEUKEMIAS IN 2014: SOME UNRESOLVED ISSUES

Chairmen: Jacob M. Rowe Sergio Amadori

8.15 IntroductionJacob M. Rowe

8.20 The increasing role of mutations and genomicsBrunangelo Falini

8.40 The increasing clinical relevance of minimal residual disease Gert J. Ossenkoppele

9.00 Is there a role of adjunctive therapy to standard 3+7?Alan K. Burnett

9.20 Optimal non-transplant post remission therapyJacob M. Rowe

9.40 Allogeneic transplant for older patients: GITMO experienceAlessandro Rambaldi

10.00 Therapy of a fit 70 years old individualRichard F. Schlenk

10.20 APL in 2014: next challenges for the final cureFrancesco Lo Coco

10.40 Conclusions and general discussionSergio Amadori

10.45 Coffee break

11.00 Plenary LectureRegulation of self renewal in cancer stem cellsPier Giuseppe Pelicci Presented by: Roberto M. Lemoli

SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL NEOPLASIAS

Chairman: Francesco Menichetti

11.30 Pathophysiology and clinical features Valerio Del Bono

11.50 Infections with multidrug-resistant pathogensGian Maria Rossolini

5

12.10 Neutropenic Enterocolitis: a life threatening complicationsEdoardo Benedetti

12.30 IgM concentrated: rationale for its use in hematology in the era of “bad bugs”Fabio Tumietto

12.50 IgM enriched immunoglobulins and defribotide after allogenic hematopoietic transplantation in acute leukemia Giuseppe Milone

13.15 Lunch

CHRONIC LYMPHOCYTIC LEUKEMIA

Chairmen: Enrica Morra Giovanni Pizzolo

15.00 IntroductionManlio Ferrarini

15.10 NoTCH1 mutations: pathogenesis and clinical significanceDavide Rossi

15.30

Transforming response prediction to chemo-immunotherapy using genome technologies Anna Schuh

15.50 Do the next molecular markers have an impact in treatment strategy? Gianluca Gaidano

16.10 First line therapy: which are the options today?Marco Montillo

16.30 Ultra-high risk patients: definition and treatment pathway in the era of novel drug landscapePeter Dreger

16.50 Break

17.10 Second line therapy: what are the options today? Véronique Leblond

17.30 Immunotherapeutic strategies including transplantJohn G. Gribben

17.50 A look at the future: new options?George Follows

18.10 Conclusions and general discussionEnrica Morra, Giovanni Pizzolo

FRIDAY, MAY 23

CHRONIC MYELOID LEUKEMIAS: WHAT IS NEW?

Chairmen: Rudiger Hehlmann Angelo M. Carella

8.00 IntroductionRudiger Hehlmann

8.05 The basis for clinical heterogeneityGiuseppe Saglio

8.25 Initial choice of therapyMichele Baccarani

6

8.45 Molecular monitoringAndreas Hochhaus

9.05 Alternative approaches in eradicating the malignant cloneRichard A. Van Etten

9.25 Early molecular response is predictive of long-term outcome?Susan Branford

9.45 Current clinical options after resistance/intolerance to 1G/2G TKIsFabrizio Pane

10.05 Blastic crisis managementRudiger Hehlmann

10.25 When should we transplant?Jane Apperley

10.45 Coffee break

11.00 Safety profiles of different TKIsCarlo Gambacorti-Passerini

11.20 How will we manage CML in the next decade?Stephen O’Brien

11.40 Conclusions and general discussionAngelo M. Carella

NEW MOLECULAR INSIGHTS AND THERAPEUTIC STRATEGIES IN ACUTE LYMPHOCYTIC LEUKEMIA

Chairmen: Dieter Hoelzer Felicetto Ferrara

11.45 IntroductionDieter Hoelzer

11.50 New markers for the diagnosis of ALL: including NGS? Robin Foà / Sabina Chiaretti

12.10 Minimal residual disease: comparison of different methods Monika Brüggemann

12.30 Current treatment results without antibodiesRenato Bassan

12.50 Antibody therapyDieter Hoelzer

13.10 Targeted therapyOliver G. Ottmann

13.30 Lunch

15.00 Risk factors and therapy in adult T-ALL Vahid Asnafi

15.20 Stem cell transplantation Andrea Bacigalupo

15.40 Conclusions and general discussion Felicetto Ferrara

16.00 Break

MYELODYSPLASTIC SYNDROMES

Chairmen: Giorgina SpecchiaPellegrino Musto

16.15 IntroductionGiorgina Specchia

16.20 ClassificationPellegrino Musto

7

16.40 Prognostic models to predict survivalValeria Santini

17.00 Low-risk patients with deletions in chromosome 5Esther N. Oliva

17.20 Therapeutic strategiesGiorgina Specchia

17.40 Five years after Azacitidine approval: remaining challengesThomas Prebet

18.00 Who should be transplanted and when?Maria Teresa Voso

18.20 Conclusions and general discussionPellegrino Musto

SATURDAY, MAY 24

PH-NEGATIVE MYELOPROLIFERATIVE SYNDROMES

Chairmen: Tiziano BarbuiMarco Gobbi

9.00 IntroductionTiziano Barbui

9.10 Molecular diagnosis of MPNs in practice Robert Kralovics

9.30 Molecular prognostic profiling in primitive myelofibrosis Alessandro Vannucchi

9.50 Therapeutic challenges in PV and ET patients conventionally classified at low-risk for thrombosisTiziano Barbui

10.10 Prefibrotic myelofibrosis: a diagnosis that counts Giovanni Barosi

10.30 Are we ready for treatment recommendations with Ruxolitinib in myelofibrosis? Jean-Jacques Kiladjian

10.50 Deciding hematopoietic stem-cell transplant in myelofibrosis Nicolaus Kröger

11.10 Conclusions and general discussionMarco Gobbi

11.40 End of the conference

8

Daniele Alberti, Origgio, MI (I)Sergio Amadori, Roma (I)Emanuele Angelucci, Cagliari (I)Jane F. Apperley, London (UK)William Arcese, Roma (I)Vahid Asnafi, Paris (F)Michele Baccarani, Bologna (I)Andrea Bacigalupo, Genova (I)Tiziano Barbui, Bergamo (I)Giovanni Barosi, Pavia (I)Renato Bassan, Venezia (I)Edoardo Benedetti, Pisa (I)Alf Bernhardt, Basel (CH)Alberto Bosi, Firenze (I)Susan Branford, Adelaide (AUS) Monika Brüggemann, Kiel (D)Alan K. Burnett, Cardiff (UK)James Carmichael, Seville (S)Sabina Chiaretti, Roma (I)Fabio Ciceri, Milano (I)Adam Craig, South San Francisco (USA)Valerio Del Bono, Genova (I)Peter Dreger, Heidelberg (D)Andreas Engert, Cologne (D)Brunangelo Falini, Perugia (I)Massimo Federico, Modena (I)

Manlio Ferrarini, Genova (I)

George Follows, Cambridge (UK)

Robin Foà, Roma (I)

Gianluca Gaidano, Novara (I)

Carlo Gambacorti-Passerini, Monza (I)

Marco Gobbi, Genova (I)

John G. Gribben, London (UK)

Rudiger Hehlmann, Heidelberg (D)

Andreas Hochhaus, Jena (D)

Dieter Hoelzer, Frankfurt (D)

Jean-Jacques Kiladjian, Paris (F)

Robert Kralovics, Vienna (A)

Nicolaus Kröger, Hamburg (D)

Véronique Leblond, Paris (F)

Roberto M. Lemoli, Genova (I)

Francesco Lo Coco, Roma (I)

Giovanni Martinelli, Bologna (I)

Francesco Menichetti, Pisa (I)

Giuseppe Milone, Catania (I)

Marco Montillo, Milano (I)

Pellegrino Musto, Rionero in Vulture, PZ (I)

Stephen O’Brien, Newcastle (UK)

Esther Natalie Oliva, Reggio Calabria (I)

Gert J. Ossenkoppele, Amsterdam (NL)

Oliver G. Ottmann, Frankfurt (D)

Fabrizio Pane, Napoli (I)

Pier Giuseppe Pelicci, Milano (I)

Danilo Perrotti, Baltimore (USA)

Giovanni Pizzolo, Verona (I)

Thomas Prebet, Marseille (F)

Alessandro Rambaldi, Bergamo (I)

Davide Rossi, Novara (I)

Giuseppe Rossi, Brescia (I)

Gian Maria Rossolini, Siena (I)

Jacob M. Rowe, Jerusalem (IL)

Giuseppe Saglio, Orbassano, TO (I)

Valeria Santini, Firenze (I)

Richard F. Schlenk, Ulm (D)

Anna Schuh, Oxford (UK)

Giorgina Specchia, Bari (I)

Fabio Tumietto, Bologna (I)

Richard A. Van Etten, Orange CA, (USA)

Alessandro M. Vannucchi, Firenze (I)

Maria Teresa Voso, Roma (I)

Pier Luigi Zinzani, Bologna (I)

Angelo Michele Carella U.O.C. Ematologia IIRCCS A.O.U. San Martino-ISTGenova (I)

Felicetto Ferrara U.O. Ematologia e Trapianto di Midollo OsseoA.O. A. CardarelliNapoli (I)

Enrica Morra U.O. Ematologia e Trapianto di MidolloA.O. Ospedale Niguarda Cà GrandaMilano (I)

SCIENTIFIC COORDINATORS

SPEAKERS AND CHAIRMEN

9

CME Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31) will assign 16,5 CME credits to the activity 31-86981.The Meeting is addressed to Physicians specialized in Hematology, Oncology and Biologists.It will not be possible to give Credits to physicians specialized in different fields.The credit certification is subject to:- attendance at the entire Meeting- the completion of the Meeting evaluation form- the completion of the final questionnaire (at least 75% of correct answers)

REGISTRATIONThe registration fee is € 150,00 tax free.To register, please send:- registration form duly filled out (even when sponsored by a Pharmaceutical Company)- privacy statement and consent regarding personal information (back of the form)- payment to Accademia Nazionale di Medicina – Via Martin Piaggio 17/6 - 16122 Genova fax 010 83794260 – email: registration@accmed.org, by May 12, 2014Online registration is possible on the website www.accmed.org By submitting the form and the payment, your registration is completed with the exception of specific decisions of the Meeting Secretariat.Incomplete registration will not be admitted.The registration will be confirmed by e-mail, please indicate your e-mail address on the registration form.

Cancellation

- If the participants minimum number is not reached, Accademia Nazionale di Medicina will advise by a written communication and proceed with the total refund of the fee.

- In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Cancellations after that deadline will not be refounded.

10

VENUEGrand Hotel MiramareVia Milite Ignoto, 30Santa Margherita Ligure (GE), Italy

How to reach the meeting venue:

By train the nearest train station is Santa Margherita Ligure, located 1,5 km fromthe meeting venue.

By carFrom A12 motorway please take “Rapallo” exit an then follow signs to SantaMargherita Ligure (about 5 km) and continue on the road along the seaside.Grand Hotel Miramare is located just a few meters after S. Margherita port.

By planeGenoa airport is located 30 km away from the meeting venue.

PROMOTED BYACCADEMIA NAZIONALE DI MEDICINA

www.accmed.orgGeneral Manager: Stefania Ledda

ORGANIZING PARTNERForum ServiceVia Martin Piaggio 17/616122 Genoa

Information and registrationPh. +39 010 83794233Fax +39 010 83794260registration@accmed.org

Hotel bookingPh. +39 010 83794233Fax +39 010 83794261booking@accmed.org

11

WITH THE PATRONAGE OFSocietà Italiana di Ematologia - SIESocietà Italiana di Ematologia Sperimentale - SIES

With the unconditioned contribution of

Platinum Sponsor

Gold Sponsor

Silver Sponsor

Bronze Sponsor

®